{"data":{"id":"us-in/ic-16-42-23-4","jurisdiction":"us-in","citation":"IC 16-42-23-4","heading":"Construction of chapter","body":"Sec. 4. (a) This chapter does not constitute an endorsement of amygdalin (laetrile) for the treatment of a malignancy, a disease, an illness, or a physical condition.\n(b) This chapter does not prevent a physician from prescribing amygdalin (laetrile) as a dietary supplement to a patient not suffering from a known malignancy, disease, illness, or physical condition upon execution of the written informed request.","path":["TITLE 16. HEALTH","ARTICLE 42. REGULATION OF FOOD, DRUGS, AND COSMETICS","Chapter 23. Drugs: Use of Amygdalin (Laetrile)"],"source_url":"https://iga.in.gov/ic/2026/Title_16.html#16-42-23-4","current_through":"2026","vintage":"2026","retrieved_at":"2026-09-11T20:02:18Z","sha256":"608b08c394be68766a0bd10892012ddf5a27897f07a448dc8f41f65723ed2534","source_id":"us-in","stale":false,"prev":"us-in/ic-16-42-23-3","next":"us-in/ic-16-42-23-5"},"notice":"GroundRules: Original legal text. Not legal advice."}